Surrozen (NASDAQ:SRZN) & Scienture (NASDAQ:SCNX) Critical Survey

Surrozen (NASDAQ:SRZN) and Scienture (NASDAQ:SCNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Profitability

This table compares Surrozen and Scienture’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	-274.42%	-545.43%	-64.40%
Scienture	-10,364.22%	-24.47%	-19.30%

Volatility and Risk

Surrozen has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Scienture has a beta of 3.11, indicating that its stock price is 211% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Surrozen and Scienture, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1	0	2	0	2.33
Scienture	1	0	0	0	1.00

Surrozen currently has a consensus price target of $38.50, indicating a potential upside of 178.18%. Given Surrozen’s stronger consensus rating and higher possible upside, analysts plainly believe Surrozen is more favorable than Scienture.

Insider and Institutional Ownership

66.6% of Surrozen shares are held by institutional investors. Comparatively, 5.7% of Scienture shares are held by institutional investors. 43.5% of Surrozen shares are held by company insiders. Comparatively, 49.7% of Scienture shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Surrozen and Scienture”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$10.65 million	11.14	-$63.56 million	($14.42)	-0.96
Scienture	$128,202.00	136.38	$9.07 million	N/A	N/A

Scienture has lower revenue, but higher earnings than Surrozen.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.